Element Biosciences unveils high-throughput DNA sequencer and multiomics platform in Seoul

Element Biosciences, a San Diego-based genomics company funded heavily by Samsung Electronics, began a global road show in Seoul to introduce its latest technologies. The centerpiece, Vitari, is a compact, high-throughput DNA sequencer that the company says delivers 99.99% accuracy and processes over five times more data per run than current systems, potentially reducing the price of sequencing a human genome to roughly $100.

Alongside Vitra, Element announced the forthcoming Cytos platform, which integrates physical, protein and gene-expression measurements of individual cells to accelerate drug discovery and disease research. Samsung, having invested $175 million in the Series E round, is the firm’s largest shareholder. The event at Ryse Hotel featured talks by co-founders Molly He and Michael Previte and collaborations with Samsung Medical Center, KAIST and Yonsei University College of Medicine, covering applications in cancer, immunology and agricultural genomics. Pre-orders for Vitari are already underway, with deliveries expected by the close of 2026, and the road show will continue in San Diego, Munich, Boston and Stockholm.